Sun Pharma Corporate Overview

Key Deals & Rationale Year Deals Country 2016 Acquired 14 brands from Novartis Japan Distribution agreement with 2016 India AstraZeneca 2016 Distribution agreement with AstraZeneca India 2015 Acquired InSite Vision Inc. US 2015 Distribution agreement with AstraZeneca India Rationale SUN PHARMA Entry into Japan Distribution services agreement in India for brand “Oxra" & "Oxramet"Ⓡ (brands of dapagliflozin, used for diabetes treatment) Distribution services agreement in India for brand "Oxra" & "Oxramet"Ⓡ (brands of dapagliflozin, used for diabetes treatment) Strengthens branded ophthalmic portfolio in U.S. Distribution services agreement in India for brand "Axcer"Ⓡ (brand of ticagrelor, used for the treatment of acute coronary syndrome) Strengthen position in the Global Generic Pharma Industry, No.1 Pharma Company in India & Strong positioning in Emerging Markets Strengthening the specialty product pipeline Access to sterile injectable capacity in the US Access to specialty drug-device combination in dermatology segment Access to dermatology generic portfolio Manufacturing facilities at Israel & Canada Global 2015 Sun Pharma - Ranbaxy Merger Markets In-licensing agreement with Merck for Global 2014 Tildrakizumab a biologic for psoriasis Markets 2014 Acquired Pharmalucence US 2012 Acquired DUSA Pharma, Inc. US Acquired Taro Pharmaceutical 2010 Israel Industries Ltd. 1997 Acquired Caraco Detroit, Entry into US Market US © Sun Pharmaceutical Industries Limited. All Rights Reserved. 16

View entire presentation